Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Viracta Therapeutics, Inc. | snss-ex321_9.htm |
| EX-31.2 - EX-31.2 - Viracta Therapeutics, Inc. | snss-ex312_8.htm |
| EX-31.1 - EX-31.1 - Viracta Therapeutics, Inc. | snss-ex311_6.htm |
| EX-21.1 - EX-21.1 - Viracta Therapeutics, Inc. | snss-ex211_7.htm |
| EX-4.1 - EX-4.1 - Viracta Therapeutics, Inc. | snss-ex41_60.htm |
| 10-K - 2020 10-K - Viracta Therapeutics, Inc. | snss-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-8 No. 333-174732) pertaining to the 2011 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc., |
|
|
(2) |
Registration Statement (Form S-8 No. 333-180101) and Registration Statement (Form S-8 No. 333-187234) pertaining to the 2011 Equity Incentive Plan of Sunesis Pharmaceuticals, Inc., |
|
|
(3) |
Registration Statement (Form S-8 No. 333-195781) and Registration Statement (Form S-8 No. 333-202696) pertaining to the 2011 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc., |
|
|
(4) |
Registration Statement (Form S-8 No. 333-210183) and Registration Statement (Form S-8 No 333-223632) pertaining to the 2011 Equity Incentive Plan of Sunesis Pharmaceuticals, Inc., |
|
|
(5) |
Registration Statement (Form S-8 No. 333-217849) pertaining to the 2011 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc. |
|
|
(6) |
Registration Statement (Form S-8 No. 333-231342) pertaining to the 2011 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc., |
|
|
(7) |
Registration Statement (Form S-8 No. 333-238141) pertaining to the 2011 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc., and |
|
|
(8) |
Registration Statement (Form S-4 No. 333-251567) of Sunesis Pharmaceuticals, Inc. |
of our report dated February 24, 2021, with respect to the consolidated financial statements of Sunesis Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ ERNST & YOUNG LLP
Salt Lake City, Utah
February 24, 2021